NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 312 filers reported holding NOVOCURE LTD in Q4 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $473,681 | -34.0% | 11,414 | -4.3% | 0.53% | -34.4% |
| Q1 2023 | $717,290 | -20.4% | 11,927 | -2.9% | 0.81% | -18.7% |
| Q4 2022 | $901,105 | -4.6% | 12,285 | -1.2% | 0.99% | -9.3% |
| Q3 2022 | $945,000 | +3.7% | 12,431 | -5.2% | 1.10% | +8.5% |
| Q2 2022 | $911,000 | -17.1% | 13,106 | -1.2% | 1.01% | +9.9% |
| Q1 2022 | $1,099,000 | +8.0% | 13,263 | -2.2% | 0.92% | +13.0% |
| Q4 2021 | $1,018,000 | – | 13,562 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |